Dutch VC Forbion is hopping on the ever-lengthening SPAC train. To be led by Jasper Bos, who joined Forbion Growth as a general partner back in May just after the fund closed at $428 million, Forbion…
Bristol Myers Squibb has $4 billion hopes for its late-stage TYK2 inhibitor deucravacitinib, but the FDA’s recent negative review for the JAK inhibitor class has dampened hopes somewhat. Now, the…
J&J’s Rybrevant scored the first approval back in May for a small group of lung cancer patients with a rare EGFR mutation. Despite a swarm of other biopharma companies angling for a piece of that…
Back in July, the FDA placed a clinical hold on the Bob Langer and Flagship-backed biotech Sigilon Therapeutics for its lead program to treat hemophilia A. On Monday, Sigilon reported what caused the…
If BD’s ongoing hiring spree is any indication, the medtech giant—which recently reported nearly 20% growth in revenue for its fiscal year 2021—seems to be aiming to make an even bigger splash in…
HotSpot Therapeutics gained another $100 million to bankroll development of its allosteric medicines, which the biotech believes have a shot at treating autoimmune diseases and various cancers. The…
Fierce 15 winner Quell Therapeutics has nabbed a huge $156 million series B round for its new-look cell therapy work.
Owlet is no longer selling its Smart Sock vital sign monitors for babies and toddlers after the FDA informed the company that the devices had been improperly brought to market.
Turnstone Biologics is charging ahead with its expansion into tumor-infiltrating lymphocytes (TIL), striking a deal with Moffitt Cancer Center to complement the capabilities it picked up in its…
NYU researchers have developed a drug that prevent a protein called rage from triggering inflammatory signals in diabetes. The drug reduced the risk of heart attack and sped up the healing of diabetic…
